Tag: c-reactive protein (CRP)

1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner. 2. Thrombotic biomarkers including fibrinogen, serum amyloid A, haptoglobin, secretory phospholipase A2, and lipoprotein were lower in treatment groups compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Prior studies, including the landmark...
1. In a study of children with community acquired pneumonia, initial biomarker levels (C-reactive protein, white blood cell count, procalcitonin, absolute neutrophil count) were similar across illness severities. 2. Higher C-reactive protein and procalcitonin levels were predictive of specific severe outcomes, including empyema requiring chest drainage and septic shock. Evidence Rating...
1. In this randomized clinical trial, intravenous infusion of high-dose vitamin C vs placebo for 96 hours resulted in no significant differences in the modified Sequential Organ Failure Assessment score at 96 hours or in levels of C-reactive protein and thrombomodulin at 168 hours. 2. There were three secondary outcomes...
1. In this randomized clinical trial, intravenous infusion of high-dose vitamin C vs placebo for 96 hours resulted in no significant differences in the modified Sequential Organ Failure Assessment score at 96 hours or in levels of C-reactive protein and thrombomodulin at 168 hours. 2. There were three secondary outcomes...